FEBS Letters · 2002 · 80 citations · 15 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyChemotherapyApoptosis In CancerApoptosis ResistanceBcl-2 Family ProteinsChemotherapy ResistanceCytotoxic ChemotherapyMalignant NeoplasmsApoptosis InductionApoptosis Resistance In TumorsFrameshift MutationsMitochondrial Apoptosis PathwaysMitochondrial Apoptosis RegulationResistance ClonesTherapeutic Resistance MechanismsWestern Blotting
To investigate acquired resistance to oxaliplatin, we selected two resistant clones from the HCT116 cell line. We found that the resistant phenotype was associated with resistance to oxaliplatin-induced apoptosis as demonstrated by FACS analysis and by Western blotting of caspase 3 activation. In addition, the resistant phenotype showed a concomitant resistance to lonidamine and arsenic trioxide which are inducers of mitochondrial apoptosis. Furthermore, a complete loss of Bax expression due to a frameshift mutation was observed in the most resistant clone. Taken together, these findings suggest that altered mitochondrial-mediated apoptosis could play a role in oxaliplatin resistance.
15
I. Vermes, C. Haanen, H M Steffens-Nakken et al. · Journal of Immunological Methods · 1995 · 5.4K citations · Full text
Robert T. Greenlee, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 2000 · 3.9K citations · Full text
Role of <i>BAX</i> in the Apoptotic Response to Anticancer Agents
Lin Zhang, Jian Yu, Ben Ho Park et al. · Science · 2000 · 860 citations
Medicine, Oncology, Pharmacology +17
Olivier Rixe, Waldo Ortuzar, Manuel Álvarez et al. · Biochemical Pharmacology · 1996 · 615 citations
Medicine, Oncology, Pharmacology +15
The role of DNA mismatch repair in platinum drug resistance.
Daniel Fink, S Nebel, Stefan Aebi et al. · PubMed · 1996 · 603 citations